down arrow

Revive Therapeutics Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA7615161030
CAD
0.01
-0.13 (-89.7%)

Dec 04

CNQ

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.010.01

52 Week

0.010.04
Valuation
Technical
Day's Volume

CASH

768.1 k

Shareholding (Mar 2025)

FII

0.04%

Held by 6 FIIs

DII

99.96%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 6 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

-28.77%

stock-summary
Price to Book

1.06

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-94.83%
0%
-94.83%
6 Months
-89.26%
0%
-89.26%
1 Year
-54.06%
0%
-54.06%
2 Years
-86.61%
0%
-86.61%
3 Years
-87.63%
0%
-87.63%
4 Years
-87.47%
0%
-87.47%
5 Years
0%
0%
0.0%

Revive Therapeutics Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
7.45%
EBIT to Interest (avg)
-9.57
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.41
EV to EBIT
-5.41
EV to EBITDA
-5.41
EV to Capital Employed
1.41
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-26.02%
ROE (Latest)
-28.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 6 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 68.42% vs 0.00% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.50",
          "val2": "-1.90",
          "chgp": "73.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.60",
          "val2": "-1.90",
          "chgp": "68.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 11.11% vs 64.61% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.30",
          "val2": "-5.50",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.20",
          "val2": "-0.90",
          "chgp": "-144.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.60",
          "val2": "-6.30",
          "chgp": "11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.50
-1.90
73.68%
Interest
0.00
0.00
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
-0.60
-1.90
68.42%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 68.42% vs 0.00% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.30
-5.50
40.00%
Interest
0.00
0.00
Exceptional Items
-2.20
-0.90
-144.44%
Consolidate Net Profit
-5.60
-6.30
11.11%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 11.11% vs 64.61% in Jun 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Revive Therapeutics Ltd. stock-summary
stock-summary
Revive Therapeutics Ltd.
Pharmaceuticals & Biotechnology
Revive Therapeutics Ltd (Revive) is engaged in commercializing treatments for rare diseases, such as Cystinuria, Wilson's disease and Rett syndrome. The Company has completed a Phase II-A study for acute gout flares in the United States. The Company's business model focuses on finding new uses of old drugs with the objective of finding a partner or partners to bring the new use drug to the marketplace. The Company is focused on the development of Bucillamine for the treatment of cystinuria (REV-004). The Company's product pipeline includes Bucillamine for the treatment of acute gout flares (REV-002), Tianeptine for treatment of Rett Syndrome (REV-003), and Bucillamine for treatment of Wilson's disease (REV-005). The Company is focused on the development and commercialization of drugs for underserved medical needs. The Company is also evaluating additional drug repurposing candidates and formulations.
Company Coordinates stock-summary
Company Details
82 Richmond Street East , TORONTO CA : M5C 1P1
stock-summary
Tel: 1 905 6055535
stock-summary
http://www.revivethera.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."